Imprimis Pharmaceuticals

San Diego-based Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a pharmaceutical company dedicated to delivering high quality and innovative medicines to physicians and patients at accessible prices. Imprimis’ business is focused on its proprietary ophthalmology and urology drug formulations. The company’s pioneering ophthalmology formulation portfolio is disrupting the multi-billion dollar eye drop market, addressing patient compliance issues and providing other medical and economic benefits to patients. Imprimis launched its urology business in early 2015, which includes a patented formulation to address patients suffering from interstitial cystitis.
Type
Public
HQ
San Diego, US
Founded
2012
Size (employees)
56 (est)
Imprimis Pharmaceuticals was founded in 2012 and is headquartered in San Diego, US

Imprimis Pharmaceuticals Office Locations

Imprimis Pharmaceuticals has an office in San Diego
San Diego, US (HQ)
350 12264 El Camino Real

Imprimis Pharmaceuticals Data and Metrics

Imprimis Pharmaceuticals Financial Metrics

Imprimis Pharmaceuticals's revenue was reported to be $19.9 m in FY, 2016 which is a 105% increase from the previous period.
$, USD

Revenue (FY, 2016)

19.9 m

Revenue growth (FY, 2015 - FY, 2016), %

105%

Gross profit (FY, 2016)

10.1 m

Gross profit margin (FY, 2016), %

51%

Net income (FY, 2016)

(19.1 m)

EBIT (FY, 2016)

(15.9 m)

Market capitalization (22-Jun-2017)

67.6 m

Closing share price (22-Jun-2017)

3.3

Cash (31-Dec-2016)

8.9 m
Imprimis Pharmaceuticals's current market capitalization is $67.6 m.
$, USDFY, 2014FY, 2015FY, 2016

Revenue

1.7 m9.7 m19.9 m

Revenue growth, %

485%105%

Cost of goods sold

1.1 m5.2 m9.8 m

Gross profit

567.4 k4.5 m10.1 m

Gross profit Margin, %

34%46%51%

Operating expense total

10.7 m19.3 m26 m

EBIT

(10.1 m)(14.8 m)(15.9 m)

EBIT margin, %

(611%)(153%)(80%)

Interest expense

3.8 k1.1 m2.8 m

Interest income

32.4 k1.1 m

Income tax expense

111 k

Net Income

(10.1 m)(15.9 m)(19.1 m)
$, USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

15.6 m8.2 m2.7 m8.9 m

Accounts Receivable

81.3 k840 k2.9 m

Inventories

105.1 k372.7 k1.4 m1.8 m

Current Assets

15.7 m9.1 m5.9 m14.8 m

PP&E

7.3 m

Goodwill

331.6 k2.5 m2.2 m

Total Assets

15.8 m10.2 m14.1 m27.2 m

Accounts Payable

311.9 k786.7 k3.4 m3.5 m

Current Liabilities

650.6 k1.6 m5.4 m9.9 m

Additional Paid-in Capital

46.8 m50 m56.4 m83.3 m

Retained Earnings

(41.9 m)(57.8 m)(76.9 m)

Total Equity

15.1 m8.2 m(1.4 m)6.4 m

Financial Leverage

1 x1.3 x-10.2 x4.2 x
$, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(7.6 m)(10.1 m)(15.9 m)(19.1 m)

Depreciation and Amortization

5.7 k

Accounts Receivable

(22.9 k)(360 k)(2.1 m)

Inventories

(17 k)(159.5 k)(314 k)(429 k)

Accounts Payable

(239.8 k)345.4 k1 m1.5 m

Cash From Operating Activities

(4.4 m)(7.1 m)(11.1 m)(11.2 m)

Purchases of PP&E

(6.9 m)

Cash From Investing Activities

(70 k)(910.5 k)(5.1 m)(7.3 m)

Cash From Financing Activities

10.1 m598.1 k10.7 m24.7 m

Interest Paid

3.8 k637 k1.4 m

Income Taxes Paid

1.6 k8001 k9 k
$, USDY, 2016

Revenue/Employee

356.1 k

Financial Leverage

4.2 x

Imprimis Pharmaceuticals Market Value History

Imprimis Pharmaceuticals Online and Social Media Presence

Imprimis Pharmaceuticals News and Updates

Imprimis Pharmaceuticals Company Life and Culture

You may also be interested in